Clene Inc. Form 8-K Summary
Business context and reporting period
Clene Inc. filed a Current Report on Form 8-K dated September 18, 2023. The filing reports changes to the Board of Directors and board committee composition. It does not present quarterly or annual financial results.
Key financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material changes
- Matthew Kiernan AM, Ph.D., DSc, and Arjun (JJ) Desai, M.D., were appointed as Class II directors effective September 18, 2023. Their terms run through the 2025 Annual Meeting of Stockholders, subject to successor election and qualification.
- The Board determined that both appointees qualify as independent directors under applicable SEC and Nasdaq standards.
- John H. Stevens, M.D., retired from the Board and all committees effective immediately. The filing states that the retirement was for philanthropic reasons and was not due to disagreement with the Company.
- Jonathon T. Gay was appointed to the Audit Committee, and Dr. Desai was appointed to the Compensation Committee.
- The Audit Committee remains composed of three independent directors: Alison H. Mosca, Shalom Jacobovitz, and Mr. Gay. The Compensation Committee remains composed of three independent directors: Mr. Jacobovitz, Ms. Mosca, and Dr. Desai.
Compensation, outlook, and risks
- Under the non-employee director compensation program, each new director received options to purchase 45,000 shares of common stock.
- The options have an exercise price of $0.54 per share, equal to the closing price on Nasdaq on September 18, 2023.
- The options vest in 36 equal monthly installments beginning September 30, 2023.
- The filing provides no financial guidance, operating outlook, contingency disclosure, or new business risk factors.
- No reportable related-party transactions or appointment arrangements were disclosed for the new directors.
Facts investors should verify
- Confirm the subsequent vesting and potential dilution associated with the 90,000 director options.
- Review later filings for additional changes to board membership or committee composition.
- Consult the Company’s periodic reports for financial condition, cash runway, operating results, and clinical-development risks, which are not addressed in this filing.